The value of five blood markers in differentiating mycosis fungoides and Sézary syndrome: a validation cohort*
- 14 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (2) , 405-411
Abstract
Background Clinical and histological diagnosis of Sézary syndrome (SS) and mycosis fungoides (MF) is challenging in routine. We investigated five blood markers previously described for SS (T‐plastin, Twist, KIR3DL2, NKp46 and Tox) in a prospective validation cohort of patients. Methods The markers were analyzed by RT‐q‐PCR on peripheral blood leucocytes and CD4+ T‐cells in a cohort of consecutive patients with early MF, erythrodermic MF and SS and compared to patients presenting with benign inflammatory dermatoses (BID) and erythrodermic BID. The markers were assessed in parallel to gold standard values such as CD4/CD8 ratio, loss of CD7 and CD26 membrane expression, and CD4 absolute values. Sensitivity and specificity were analyzed by Receiver Operator Characteristics curves. The prognostic value of selected markers was analyzed on a subset of patients. Results We included 447 patients in this study and 107 patients were followed up for prognosis. We defined cutoffs for each marker. T‐plastin, Twist and KIR3DL2 had the best validity. This study was conducted in one center. SS may be overrepresented. The combination of T‐plastin and Twist was able to differentiate between erythrodermic MF or BID and SS. The additional analysis of KIR3DL2 may be useful to predict the prognosis. Conclusion We propose T‐plastin, Twist and KIR3DL2 measured by RT‐q‐PCR as new diagnostic markers for Sézary syndrome.Keywords
Funding Information
- European Society for Medical Oncology (RG2019)
This publication has 32 references indexed in Scilit:
- Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR 3 DL 2 markerBritish Journal of Dermatology, 2019
- The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomasBlood, 2019
- The PROCLIPI international registry of early‐stage mycosis fungoides identifies substantial diagnostic delay in most patientsBritish Journal of Dermatology, 2018
- Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task forceEuropean Journal of Cancer, 2018
- Use of PLS3, Twist, CD158k/KIR3DL2, and NKp46 gene expression combination for reliable Sézary syndrome diagnosisBlood, 2013
- Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of CancerJournal of Clinical Oncology, 2011
- The United States Cutaneous Lymphoma Consortium (USCLC)Clinical Lymphoma Myeloma and Leukemia, 2010
- Aberrant Expression of the Tyrosine Kinase Receptor EphA4 and the Transcription Factor Twist in Sézary Syndrome Identified by Gene Expression AnalysisCancer Research, 2004
- Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell LymphomaJournal of Experimental Medicine, 2003
- CD4+ cutaneous T-cell lymphoma cells express the p140–killer cell immunoglobulin-like receptorBlood, 2001